212 related articles for article (PubMed ID: 9322083)
1. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
[TBL] [Abstract][Full Text] [Related]
2. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-alpha.
Jorns C; Holzinger D; Thimme R; Spangenberg HC; Weidmann M; Rasenack J; Blum HE; Haller O; Kochs G
J Med Virol; 2006 Jan; 78(1):74-82. PubMed ID: 16299717
[TBL] [Abstract][Full Text] [Related]
3. [The influence of interferon alpha neutralizing antibodies on the therapeutic effectiveness in patients with chronic viral hepatitis].
Tong F; Tang Y; Bai J
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Dec; 13(4):345-7. PubMed ID: 12759973
[TBL] [Abstract][Full Text] [Related]
4. Natural leukocyte interferon-alpha therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-alpha.
Tefferi A; Grendahl DC
Am J Hematol; 1996 Jul; 52(3):231-3. PubMed ID: 8756097
[TBL] [Abstract][Full Text] [Related]
5. Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2.
Nolte KU; Günther G; von Wussow P
Eur J Immunol; 1996 Sep; 26(9):2155-9. PubMed ID: 8814261
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial.
Simon DM; Gordon SC; Kaplan MM; Koff RS; Regenstein F; Everson G; Lee YM; Weiner F; Silverman A; Plasse T; Fedorczyk D; Liao MJ
Hepatology; 1997 Feb; 25(2):445-8. PubMed ID: 9021962
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
[TBL] [Abstract][Full Text] [Related]
8. Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2.
Stancek D; Fuchsberger N; Oltman M; Schmeisser H; Kontsek P; Jahnová E; Hajnická V
Acta Virol; 2001; 45(5-6):287-92. PubMed ID: 12083327
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up after successful interferon therapy of acute hepatitis C.
Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
[TBL] [Abstract][Full Text] [Related]
10. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes.
Brand CM; Leadbeater L; Bellati G; Marotta F; Ideo G
J Interferon Res; 1993 Apr; 13(2):121-5. PubMed ID: 7685368
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of neutralizing anti-interferon antibodies in chronic hepatitis B patients treated with recombinant interferon-alpha].
Mao QG; Luo KX; Liu DL; Zhang MX; Hou JL
Zhonghua Gan Zang Bing Za Zhi; 2004 Apr; 12(4):205-7. PubMed ID: 15099466
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping.
Bello-Rivero I; Cervantes M; Torres Y; Ferrero J; Rodríguez E; Pérez J; García I; Díaz G; López-Saura P
J Autoimmun; 2004 Aug; 23(1):63-73. PubMed ID: 15236754
[TBL] [Abstract][Full Text] [Related]
13. Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection.
Bálint E; Bakay M; Onody K; Farkas F; Horváth G; Tolvaj G; Dávid K; Horányi M; Béládi I
Acta Microbiol Immunol Hung; 2004; 51(3):359-69. PubMed ID: 15571075
[TBL] [Abstract][Full Text] [Related]
14. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
von Wussow P; Jakschies D; Freund M; Deicher H
J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
[TBL] [Abstract][Full Text] [Related]
15. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies.
Fournier C; Duverlie G; François C; Schnuriger A; Dedeurwaerder S; Brochot E; Capron D; Wychowski C; Thibault V; Castelain S
Virol J; 2007 Mar; 4():35. PubMed ID: 17397531
[TBL] [Abstract][Full Text] [Related]
16. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
[TBL] [Abstract][Full Text] [Related]
17. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
Oberg K; Alm GV
J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection.
Milella M; Antonelli G; Santantonio T; Currenti M; Monno L; Mariano N; Angarano G; Dianzani F; Pastore G
Liver; 1993 Jun; 13(3):146-50. PubMed ID: 8336526
[TBL] [Abstract][Full Text] [Related]
19. [Treatment with lymphoblastoid alpha interferon in patients with chronic myeloid leukemia refractory to recombinant interferon alpha 2].
Steegmann JL; Granados E; Vázquez L; de la Cámara R; Peñarrubia MJ; Fernández-Contreras E; Quiroga JA; Fernández Rañada JM
Sangre (Barc); 1998 Oct; 43(5):443-6. PubMed ID: 9868341
[TBL] [Abstract][Full Text] [Related]
20. Low levels of hepatitis C virus (HCV) neutralizing antibodies in patients coinfected with HCV and human immunodeficiency virus.
Castelain S; Schnuriger A; François C; Nguyen-Khac E; Fournier C; Schmit JL; Capron D; Dubuisson J; Wychowski C; Thibault V; Duverlie G
J Infect Dis; 2008 Aug; 198(3):332-5. PubMed ID: 18558868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
